Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:PGNX
  • CUSIP: 74318710
  • Web: www.progenics.com
Capitalization:
  • Market Cap: $488.37 million
  • Outstanding Shares: 70,269,000
Average Prices:
  • 50 Day Moving Avg: $6.01
  • 200 Day Moving Avg: $7.45
  • 52 Week Range: $4.60 - $11.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.31
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $63.62 million
  • Price / Sales: 7.68
  • Book Value: $1.06 per share
  • Price / Book: 6.56
Profitability:
  • EBIDTA: ($958,000.00)
  • Net Margins: -6.13%
  • Return on Equity: -4.11%
  • Return on Assets: -2.20%
Debt:
  • Debt-to-Equity Ratio: 0.65%
  • Current Ratio: 7.28%
  • Quick Ratio: 7.28%
Misc:
  • Average Volume: 1.03 million shs.
  • Beta: 3.4
  • Short Ratio: 12.56
 

Frequently Asked Questions for Progenics Pharmaceuticals (NASDAQ:PGNX)

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) issued its earnings results on Wednesday, August, 9th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. The firm earned $2.77 million during the quarter, compared to analysts' expectations of $3.34 million. Progenics Pharmaceuticals had a negative net margin of 6.13% and a negative return on equity of 4.11%. The business's revenue for the quarter was down 67.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) EPS. View Progenics Pharmaceuticals' Earnings History.

When will Progenics Pharmaceuticals make its next earnings announcement?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Progenics Pharmaceuticals.

Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2017?

6 analysts have issued 1 year target prices for Progenics Pharmaceuticals' shares. Their forecasts range from $11.00 to $15.00. On average, they anticipate Progenics Pharmaceuticals' share price to reach $12.83 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.

What are analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "NDA Submission for Azedra this Month. PGNX has completed a pre- submission meeting for Azedra with the FDA and an NDA submission should follow this month. The drug has been awarded Breakthrough designation and was developed under a SPA. Top line results were released earlier this year and a fuller data set is expected to be presented at the International Symposium of Pheochromocytoma and Paraganglioma on September 1." (8/9/2017)
  • 2. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (7/5/2017)
  • 3. Needham & Company LLC analysts commented, "We recently chose PGNX as our Top Pick for 2017 and are now going one step further and upgrading it to Strong Buy. We continue to expect significant appreciation in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. Our increased $14 price target reflects the introduction of estimates for the 1404 imaging agent, which recently passed an interim analysis in its pivotal trial." (2/6/2017)

Who are some of Progenics Pharmaceuticals' key competitors?

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:

  • Peter J. Crowley, Independent Chairman of the Board
  • Mark R. Baker J.D., Chief Executive Officer, Director
  • Patrick Fabbio, Chief Financial Officer
  • Nitya G. Ray Ph.D., Senior Vice President - Manufacturing
  • Vivien Wong Ph.D., Senior Vice President - Operations and Portfolio Management
  • Ann Marie Assumma, Vice President - Regulatory Affairs
  • Karen Jean Ferrante M.D., Independent Director
  • Michael D. Kishbauch, Independent Director
  • David A. Scheinberg MD., Ph.D., Independent Director
  • Nicole S. Williams, Independent Director

Who owns Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (15.54%), Vanguard Group Inc. (6.12%), Eagle Asset Management Inc. (5.71%), State Street Corp (5.28%), FMR LLC (3.80%) and Pinnacle Associates Ltd. (3.50%). View Institutional Ownership Trends for Progenics Pharmaceuticals.

Who sold Progenics Pharmaceuticals stock? Who is selling Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Broadfin Capital LLC, Goldman Sachs Group Inc., Gotham Asset Management LLC, FMR LLC, Russell Investments Group Ltd., Alliancebernstein L.P. and Pinnacle Associates Ltd.. View Insider Buying and Selling for Progenics Pharmaceuticals.

Who bought Progenics Pharmaceuticals stock? Who is buying Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., State Street Corp, Numeric Investors LLC, Rice Hall James & Associates LLC, ING Groep NV, Vanguard Group Inc., Marshall Wace North America L.P. and GSA Capital Partners LLP. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy Progenics Pharmaceuticals stock?

Shares of Progenics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of Progenics Pharmaceuticals stock can currently be purchased for approximately $6.95.


MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.17)
Consensus Price Target: $12.83 (84.65% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017Cantor FitzgeraldReiterated RatingOverweight$15.00LowView Rating Details
9/1/2017Needham & Company LLCReiterated RatingStrong-Buy$14.00MediumView Rating Details
8/22/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Jefferies Group LLCReiterated RatingBuy$12.00HighView Rating Details
11/30/2016BTIG ResearchBoost Price TargetBuy$9.00 -> $11.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$11.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Earnings History by Quarter for Progenics Pharmaceuticals (NASDAQ PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.23)N/AView Earnings Details
8/9/2017Q2 2017($0.20)($0.24)$3.34 million$2.77 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.23)$4.50 million$2.40 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.20)($0.10)$4.43 million$4.65 millionViewListenView Earnings Details
11/7/2016Q316$0.55$0.52$52.90 million$53.90 millionViewListenView Earnings Details
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
2017 EPS Consensus Estimate: ($0.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 89.17%
Insider Trades by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Trades by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Healthcare Master Fun BroadfinMajor ShareholderSell602,600$9.66$5,821,116.00View SEC Filing  
2/9/2017Healthcare Master Fun BroadfinMajor ShareholderSell351,300$9.71$3,411,123.00View SEC Filing  
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Progenics Pharmaceuticals (NASDAQ:PGNX)
Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
Source:
DateHeadline
finance.yahoo.com logoWhat's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
finance.yahoo.com - September 19 at 6:29 AM
fool.com logoWhat's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
www.fool.com - September 18 at 2:08 PM
finance.yahoo.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 7:34 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 9:13 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : September 12, 2017
finance.yahoo.com - September 13 at 7:45 AM
seekingalpha.com logoProgenics: Draining The Azedra Quagmire - Seeking Alpha
seekingalpha.com - September 9 at 7:20 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 6 at 4:46 AM
seekingalpha.com logoProgenics's Azedra: What's Wrong With This Picture? - Seeking Alpha
seekingalpha.com - September 5 at 10:26 PM
seekingalpha.com logoWhat Would Progenics Be Worth Without Azedra? - Seeking Alpha - Seeking Alpha
seekingalpha.com - September 5 at 10:26 PM
americanbankingnews.com logoCantor Fitzgerald Reaffirms "Overweight" Rating for Progenics Pharmaceuticals Inc. (PGNX)
www.americanbankingnews.com - September 5 at 9:42 AM
finance.yahoo.com logoProgenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA®
finance.yahoo.com - September 2 at 7:29 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharmaceuticals Inc. - PGNX
finance.yahoo.com - September 2 at 7:29 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : September 2, 2017
finance.yahoo.com - September 2 at 7:29 AM
americanbankingnews.com logoProgenics Pharmaceuticals' (PGNX) "Strong-Buy" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - September 1 at 12:56 PM
streetinsider.com logoProgenics Pharma (PGNX) Reports Update on Timing of NDA Submission for AZEDRA - StreetInsider.com
www.streetinsider.com - September 1 at 7:12 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : August 30, 2017
finance.yahoo.com - August 31 at 8:41 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc.: Gathering momentum, can it sustain its performance?
finance.yahoo.com - August 30 at 7:56 AM
seekingalpha.com logoA Key Week Ahead For Progenics Pharmaceuticals - Seeking Alpha
seekingalpha.com - August 29 at 6:39 AM
seekingalpha.com logoProgenics' AZEDRA: A Minority Report - Seeking Alpha
seekingalpha.com - August 26 at 8:17 AM
seekingalpha.com logoProgenics: Unloved And Undervalued ~$5 Biotech Stock - Seeking Alpha
seekingalpha.com - August 13 at 8:04 PM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 12 at 4:32 AM
finance.yahoo.com logoProgenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update
finance.yahoo.com - August 10 at 6:50 AM
finance.yahoo.com logoEdited Transcript of PGNX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 6:50 AM
finance.yahoo.com logoHere's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
finance.yahoo.com - August 10 at 6:50 AM
finance.yahoo.com logoProgenics reports 2Q loss
finance.yahoo.com - August 10 at 6:50 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:22 PM
finance.yahoo.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 6:57 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - August 4 at 12:22 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:32 AM
finance.yahoo.com logoProgenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9
finance.yahoo.com - July 27 at 6:20 AM
finance.yahoo.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 7:56 PM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 2:45 PM
seekingalpha.com logoBiotech Forum Daily Digest: Why Progenics Could Rally This Summer - Seeking Alpha
seekingalpha.com - July 18 at 7:18 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. to Post FY2017 Earnings of ($0.99) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:PGNX)
www.americanbankingnews.com - July 17 at 8:53 AM
finance.yahoo.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 7:29 AM
finance.yahoo.com logoProgenics Shares Could Double, According To Cantor
finance.yahoo.com - July 13 at 7:55 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 5 at 8:36 AM
americanbankingnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 23 at 11:47 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : June 22, 2017
finance.yahoo.com - June 23 at 9:03 AM
finance.yahoo.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 9:03 AM
finance.yahoo.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 6:51 PM
seekingalpha.com logoProgenics Pharmaceuticals (PGNX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 7:24 PM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 7:24 PM
americanbankingnews.com logoProgenics Pharmaceuticals' (PGNX) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - June 8 at 9:10 PM
americanbankingnews.com logoZacks Investment Research Upgrades Progenics Pharmaceuticals, Inc. (PGNX) to "Hold"
www.americanbankingnews.com - June 6 at 7:06 AM
streetinsider.com logoProgenics Pharma (PGNX) Announces Presentation of Data From Two Automated Bone Scan Index Studies at ASCO
www.streetinsider.com - June 3 at 2:44 AM
streetinsider.com logoProgenics Pharma (PGNX) Announces Presentation of Data From Two Automated Bone Scan Index Studies at ASCO - StreetInsider.com
www.streetinsider.com - June 2 at 9:43 PM
finance.yahoo.com logoProgenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting
finance.yahoo.com - June 2 at 9:43 PM
nasdaq.com logoProgenics Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference - Nasdaq
www.nasdaq.com - June 1 at 8:03 PM
americanbankingnews.com logoTheStreet Lowers Progenics Pharmaceuticals, Inc. (PGNX) to D+
www.americanbankingnews.com - June 1 at 2:22 PM

Social

Chart

Progenics Pharmaceuticals (PGNX) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff